Drug Profile
Relcovaptan
Alternative Names: SR 49059Latest Information Update: 03 Oct 2006
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Class Antihormones; Indoles; Pyrrolidines; Vasodilators
- Mechanism of Action Vasopressin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary spasm; Dysmenorrhoea; Heart failure; Hypertension; Preterm labour; Small cell lung cancer
Most Recent Events
- 10 Sep 2003 Discontinued - Phase-II for Small cell lung cancer in France (PO)
- 10 Sep 2003 Discontinued - Preclinical for Coronary spasm in France (PO)
- 04 Sep 2001 Discontinued-Clinical for Preterm labour in Poland (PO)